Financial Information

Balance Sheet

v3.8.0.1
Consolidated Balance Sheets - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Current Assets    
Cash $ 562,760 $ 182,561
Trade accounts receivable, net 276,992 444,743
Other receivables 2,250
Product deposit 119,899
Inventory, net 377,800 160,270
Total Current Assets 1,337,451 789,824
Current Liabilities    
Accounts payable and accrued expenses 699,651 752,930
Derivative liabilities 192,254
Convertible notes payable 100,000
Notes payable, net of discount in 2016 77,333 106,365
Total Current Liabilities 776,984 1,151,549
Stockholders' Equity (Deficit)    
Common stock, $0.01 par value; 100,000,000 shares authorized, 44,257,342 and 35,570,157 shares issued, 43,742,142 and 35,245,157 outstanding as of September 30, 2017 and December 31, 2016, respectively 442,573 355,701
Additional paid-in capital 11,218,988 9,070,064
Accumulated (deficit) (10,680,261) (9,693,882)
Equity 981,300 (268,117)
Treasury stock, 515,200 and 325,000 shares, at cost (163,701) (87,053)
Total Immudyne, Inc. Stockholders' (Deficit) 817,599 (355,170)
Non-controlling interest (257,132) (6,555)
Total Stockholders' (Deficit) 560,467 (361,725)
Total Liabilities and Stockholders' (Deficit) $ 1,337,451 $ 789,824

Source